{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109"}]}],"title":"ATA positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"nATA positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"632"}],"units":"Participants"}],"description":"The nATA positive was defined as positive ATA with neutralizing activity at any postbaseline visit.","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"}],"paramType":"NUMBER","populationDescription":"The safety population included all enrolled participants who received at least 1 dose of any study drug. The safety population-immunogenicity-evaluable participants where baseline and at least one postbaseline sample was available.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment (approximately 1 year)","title":"A+AVD: Number of Participants With Antitherapeutic Antibody (ATA) and Neutralizing Antitherapeutic Antibody (nATA) Positive for Brentuximab Vedotin","type":"SECONDARY","unitOfMeasure":"participants"}